Takeda's Vidoju mono-resistance is approved in China for the treatment of moderate to severe active ulcerative colitis and Crohn's disease
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Takeda Pharmaceuticals announced that its Entyvio (Vidoju mono-resistance) is approved by the China Drug Administration (NMPA) for the treatment of adult patients with moderate to severe active ulcerative colitis (UC) or Crohn's disease (CD)These patients were under-reacted or intolerant to conventional therapy or tumor necrosis factor alpha (TNF-alpha) inhibitors"Thank you very much to NMPA for officially approving Entyvio for the treatment of patients in China," said Sean Shan, president ofTakeda ChinaThis approval gives clinicians more treatment options and enables more IBD patients to return to normal lifeulcerative colitis (UC) and Crohn's disease (CD) are the two most common types of inflammatory bowel disease (IBD)Both UC and CD are chronic and recurrent inflammatory diseases of the gastrointestinal tractUC only covers the large intestine, while CDs may affect any part from the mouth to the anusUC usually manifests itself as abdominal discomfort and sagging saggingCD usually shows symptoms of abdominal pain, diarrhea and weight lossThe cause of the UC or CD is not entirely clearVidozumab is a human-derived monoclonal antibody designed for specific antagonistic alpha 4beta7 projumital protein, inhibiting the combination of alpha 4beta7 integral protein and intestinal mucosal address cell adhesion molecule 1 (MAdCAM-1)Vidozumab can limit the immersion of inflammatory cells into intestinal tissue by inhibiting alpha 4 beta7 whole-linked proteins
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
